RxDoctor Payments Data

John Baker, MD

Interventional Cardiology · Santa Ana, CANPI 1124022850

Payments from drug & device makers

$3,734in general payments, 2019–2025

Across 52 payments — averaging $71.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AstraZeneca$364
  • Novartis$301
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$250
  • Amgen$245
  • Shockwave Medical, Inc$225
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$1454%
  • Travel & lodging$92425%
  • Food & beverage$2,64371%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,734 in reported general payments places this provider in the 25th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$87,705
Medicare patients
1,034
Services billed
1,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$186,461
EntrestoSacubitril/Valsartan107$135,904
FarxigaDapagliflozin Propanediol42$49,519
XareltoRivaroxaban29$37,791
JardianceEmpagliflozin13$19,215
Praluent PenAlirocumab13$6,981
DapagliflozinDapagliflozin Propanediol12$6,786
Labetalol Hcl107$3,412
Nifedipine ErNifedipine82$2,149
Metoprolol Succinate142$1,858
Losartan Potassium94$770
Isosorbide Mononitrate ErIsosorbide Mononitrate65$747
Carvedilol82$737
Metoprolol Tartrate90$727
Spironolactone55$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$301$135,904107 claims
AstraZenecaFarxiga$364$49,51942 claims
Boehringer IngelheimJardiance$125$19,21513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →